Director Alex G. Howarth filed a Form 4 with the SEC on November 4, 2026, disclosing the acquisition of stock options covering 160,000 shares of Altimmune, Inc. common stock, with a transaction date of November 2, 2026.

Key Highlights

  • Reporting person: Alex G. Howarth, identified as a Director of Altimmune, Inc. (NASDAQ:ALT)
  • Security acquired: Stock options (option to buy) covering 160,000 shares of Common Stock, par value $0.0001
  • Exercise price: $2.02 per share
  • Transaction date: November 2, 2026, with an expiration date of November 2, 2036
  • Price paid: $0 for the derivative security
  • Post-transaction holdings: 160,000 derivative securities beneficially owned, held directly
  • Vesting schedule: Options vest in substantially equal monthly installments over 36 months following November 2, 2026, subject to continued service

Altimmune Director Howarth Acquires Options Vesting Over 36 Months

According to the Form 4 filed on November 4, 2026, Alex G. Howarth, a director of Altimmune, Inc., acquired stock options to purchase 160,000 shares of the company's common stock. The transaction was coded "A" (acquired) and carried a transaction date of November 2, 2026. The filing identifies the issuer as Altimmune, Inc., trading on NASDAQ:ALT.

The filing discloses that the options carry an exercise price of $2.02 per share and are set to expire on November 2, 2036. The price of the derivative security at the time of the award was reported as $0. Following the transaction, Howarth beneficially owns 160,000 derivative securities directly, with no non-derivative securities reported in Table I of the filing.

As noted in the explanation of responses, "the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following November 2, 2026, subject to the reporting person's continued service through the applicable vesting date." The form was signed by Gregory Weaver as Attorney-in-Fact on behalf of Howarth and filed on November 4, 2026.

What Was Disclosed

Altimmune director Alex G. Howarth disclosed the acquisition of stock options covering 160,000 shares at an exercise price of $2.02, expiring November 2, 2036, vesting monthly over 36 months subject to continued service, with no cash consideration paid for the award.